Search research articles
Contact Us
Filters
Showing results (21-30 of 93) with videos related to
Page
of 10
Sort By:
Future Oncology (London, England)
|
March 2, 2026
Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study
Jose C Villasboas, Michelle Poon, Monica Tani, et al.
Leukemia & Lymphoma
|
July 12, 2017
A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma
Brian T Hill, Mitchell R Smith, Meredeth Shelley, et al.
Therapeutic Advances in Hematology
|
April 7, 2018
Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant
Joshua Allen, Ana Lucia Ruano Mendez, Lisa Rybicki, et al.
Journal of Clinical Apheresis
|
August 6, 2019
Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation
Jack Khouri, Lisa Rybicki, Navneet S Majhail, et al.
The Oncologist
|
August 10, 2022
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
Deepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 10, 2017
Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
Moaath Mustafa Ali, Lisa Rybicki, Laila Nomani, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society
|
May 19, 2019
Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma
Shafia Rahman, Lisa Rybicki, Betty Ky Hamilton, et al.
Seminars in Hematology
|
January 29, 2021
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies
Brian Hill, Deepa Jagadeesh, Brad Pohlman, et al.
The Lancet. Oncology
|
July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
John M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Leukemia
|
August 12, 2023
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma
Neetha Parameswaran, Liping Luo, Lingjun Zhang, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 93) with videos related to
Sort By:
Page
of 10
Future Oncology (London, England)
|
March 2, 2026
Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study
Jose C Villasboas, Michelle Poon, Monica Tani, et al.
Leukemia & Lymphoma
|
July 12, 2017
A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma
Brian T Hill, Mitchell R Smith, Meredeth Shelley, et al.
Therapeutic Advances in Hematology
|
April 7, 2018
Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant
Joshua Allen, Ana Lucia Ruano Mendez, Lisa Rybicki, et al.
Journal of Clinical Apheresis
|
August 6, 2019
Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation
Jack Khouri, Lisa Rybicki, Navneet S Majhail, et al.
The Oncologist
|
August 10, 2022
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
Deepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 10, 2017
Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
Moaath Mustafa Ali, Lisa Rybicki, Laila Nomani, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society
|
May 19, 2019
Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma
Shafia Rahman, Lisa Rybicki, Betty Ky Hamilton, et al.
Seminars in Hematology
|
January 29, 2021
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies
Brian Hill, Deepa Jagadeesh, Brad Pohlman, et al.
The Lancet. Oncology
|
July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
John M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Leukemia
|
August 12, 2023
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma
Neetha Parameswaran, Liping Luo, Lingjun Zhang, et al.
Page
of 10